CA2397292A1 - Production de cellules - Google Patents
Production de cellules Download PDFInfo
- Publication number
- CA2397292A1 CA2397292A1 CA002397292A CA2397292A CA2397292A1 CA 2397292 A1 CA2397292 A1 CA 2397292A1 CA 002397292 A CA002397292 A CA 002397292A CA 2397292 A CA2397292 A CA 2397292A CA 2397292 A1 CA2397292 A1 CA 2397292A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- neurectoderm
- cell
- neural
- differentiated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 404
- 210000004275 neurectoderm cell Anatomy 0.000 claims abstract description 147
- 230000001537 neural effect Effects 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 97
- 230000004069 differentiation Effects 0.000 claims abstract description 89
- 239000003636 conditioned culture medium Substances 0.000 claims abstract description 43
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 14
- 230000014509 gene expression Effects 0.000 claims description 148
- 210000004556 brain Anatomy 0.000 claims description 53
- 210000002569 neuron Anatomy 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 210000004498 neuroglial cell Anatomy 0.000 claims description 36
- 210000003061 neural cell Anatomy 0.000 claims description 35
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 33
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 33
- 210000003981 ectoderm Anatomy 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 32
- 238000000338 in vitro Methods 0.000 claims description 31
- 239000003102 growth factor Substances 0.000 claims description 29
- 210000001982 neural crest cell Anatomy 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 28
- 239000002609 medium Substances 0.000 claims description 28
- 238000012258 culturing Methods 0.000 claims description 25
- 238000001727 in vivo Methods 0.000 claims description 23
- 108010088225 Nestin Proteins 0.000 claims description 19
- 230000003827 upregulation Effects 0.000 claims description 19
- 102000008730 Nestin Human genes 0.000 claims description 18
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 18
- 210000005055 nestin Anatomy 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 18
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 17
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 claims description 17
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 17
- 230000003828 downregulation Effects 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 15
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 14
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 14
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 14
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 10
- 210000001654 germ layer Anatomy 0.000 claims description 10
- 230000002518 glial effect Effects 0.000 claims description 10
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 claims description 9
- 101100203200 Danio rerio shha gene Proteins 0.000 claims description 9
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000000059 patterning Methods 0.000 claims description 9
- 101150088976 shh gene Proteins 0.000 claims description 9
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 claims description 8
- 102000007354 PAX6 Transcription Factor Human genes 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
- 210000004602 germ cell Anatomy 0.000 claims description 8
- 108010051748 Early Growth Response Protein 2 Proteins 0.000 claims description 7
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 7
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 7
- 101150013773 Hoxa7 gene Proteins 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 101150081664 PAX6 gene Proteins 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 6
- 101150041192 Otx1 gene Proteins 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 6
- 210000002637 putamen Anatomy 0.000 claims description 6
- 244000309466 calf Species 0.000 claims description 5
- 238000002659 cell therapy Methods 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 101100071843 Mus musculus Hoxb1 gene Proteins 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000032459 dedifferentiation Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 208000001608 teratocarcinoma Diseases 0.000 claims description 4
- 210000001103 thalamus Anatomy 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 3
- 239000002458 cell surface marker Substances 0.000 claims description 3
- 210000005153 frontal cortex Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 101100163882 Mus musculus Ascl1 gene Proteins 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 101150077014 sox10 gene Proteins 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 57
- 210000002242 embryoid body Anatomy 0.000 description 44
- 230000018109 developmental process Effects 0.000 description 36
- 241000700159 Rattus Species 0.000 description 35
- 238000011161 development Methods 0.000 description 35
- 239000005090 green fluorescent protein Substances 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 210000000276 neural tube Anatomy 0.000 description 26
- 230000001413 cellular effect Effects 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 210000001161 mammalian embryo Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 19
- 238000011065 in-situ storage Methods 0.000 description 19
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 210000001900 endoderm Anatomy 0.000 description 14
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 13
- 230000024245 cell differentiation Effects 0.000 description 12
- 210000000933 neural crest Anatomy 0.000 description 12
- 210000003716 mesoderm Anatomy 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 238000010009 beating Methods 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 210000001259 mesencephalon Anatomy 0.000 description 10
- 210000001178 neural stem cell Anatomy 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 210000004129 prosencephalon Anatomy 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000001202 rhombencephalon Anatomy 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000013020 embryo development Effects 0.000 description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 210000001020 neural plate Anatomy 0.000 description 8
- 238000004114 suspension culture Methods 0.000 description 8
- 210000003140 lateral ventricle Anatomy 0.000 description 7
- 210000005155 neural progenitor cell Anatomy 0.000 description 7
- 230000001360 synchronised effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000002787 antisense oligonuctleotide Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000009278 visceral effect Effects 0.000 description 6
- 108700005087 Homeobox Genes Proteins 0.000 description 5
- 101150096752 NCAM1 gene Proteins 0.000 description 5
- 238000004115 adherent culture Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 238000002991 immunohistochemical analysis Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000001705 ectoderm cell Anatomy 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- BPJYAXCTOHRFDQ-UHFFFAOYSA-L tetracopper;2,4,6-trioxido-1,3,5,2,4,6-trioxatriarsinane;diacetate Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].CC([O-])=O.CC([O-])=O.[O-][As]1O[As]([O-])O[As]([O-])O1.[O-][As]1O[As]([O-])O[As]([O-])O1 BPJYAXCTOHRFDQ-UHFFFAOYSA-L 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 101150010353 Ascl1 gene Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 101100460498 Mus musculus Nkx2-2 gene Proteins 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- 241000736774 Uria aalge Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 210000004002 dopaminergic cell Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003059 ependyma Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000008567 mammal embryogenesis Effects 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008043 neural expression Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101150059401 EGR2 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101150028927 Hoxa1 gene Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 241001071861 Lethrinus genivittatus Species 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 101100285407 Mus musculus En1 gene Proteins 0.000 description 1
- 101100507918 Mus musculus Hoxa7 gene Proteins 0.000 description 1
- 101000781965 Mus musculus Proto-oncogene Wnt-1 Proteins 0.000 description 1
- 101100149887 Mus musculus Sox10 gene Proteins 0.000 description 1
- -1 N-Cam Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 101150092239 OTX2 gene Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027886 Parkinson disease 15 Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003037 cerebral aqueduct Anatomy 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001811 primitive streak Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ5098A AUPQ509800A0 (en) | 2000-01-14 | 2000-01-14 | Cell production |
| AUPQ5098 | 2000-01-14 | ||
| AUPQ7045A AUPQ704500A0 (en) | 2000-04-20 | 2000-04-20 | Cell production |
| AUPQ7045 | 2000-04-20 | ||
| AUPQ7143A AUPQ714300A0 (en) | 2000-04-27 | 2000-04-27 | Cell production |
| AUPQ7143 | 2000-04-27 | ||
| PCT/AU2001/000030 WO2001051611A1 (fr) | 2000-01-14 | 2001-01-12 | Production de cellules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2397292A1 true CA2397292A1 (fr) | 2001-07-19 |
Family
ID=27158200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002397292A Abandoned CA2397292A1 (fr) | 2000-01-14 | 2001-01-12 | Production de cellules |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1254211A4 (fr) |
| CA (1) | CA2397292A1 (fr) |
| WO (2) | WO2001051611A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| WO2002064748A2 (fr) | 2001-02-14 | 2002-08-22 | Furcht Leo T | Cellules souches adultes totipotentes, sources de ces cellules, procedes d'obtention et de maintien de ces dernieres, procedes de differentiation de ces cellules, procedes d'utilisation correspondants et cellules derivees des cellules susmentionnees |
| US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
| US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
| KR20130072272A (ko) | 2001-12-07 | 2013-07-01 | 제론 코포레이션 | 인간 배아 줄기세포 유래의 조혈세포 |
| IL162131A0 (en) | 2001-12-07 | 2005-11-20 | Geron Corp | Islet cells from human embryonic stem cells |
| US20050101014A1 (en) | 2002-07-11 | 2005-05-12 | Keirstead Hans S. | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US7153650B2 (en) | 2003-03-13 | 2006-12-26 | Geron Corporation | Marker system for preparing and characterizing high-quality human embryonic stem cells |
| US8426200B2 (en) | 2003-07-02 | 2013-04-23 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
| GB2431165B (en) | 2004-07-13 | 2009-04-01 | Geron Corp | Medium for growing human embryonic stem cells |
| AU2006262329B2 (en) | 2005-06-22 | 2011-04-07 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
| GB2441488C (en) | 2005-06-22 | 2011-10-05 | Geron Corp | Suspension culture of human embryonic stem cells |
| US8415153B2 (en) | 2006-06-19 | 2013-04-09 | Geron Corporation | Differentiation and enrichment of islet-like cells from human pluripotent stem cells |
| EP2087101A2 (fr) | 2006-11-24 | 2009-08-12 | Regents of the University of Minnesota | Cellules progénitrices endothermiques |
| SG188096A1 (en) | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| JP5734836B2 (ja) | 2008-03-27 | 2015-06-17 | アステリアス バイオセラピューティクス インコーポレイテッド | 霊長類多能性幹細胞の造血系統細胞への分化 |
| GB0906424D0 (en) | 2009-04-09 | 2009-05-20 | Antoxis Ltd | Use of compounds for differentiation of cells |
| WO2011091048A1 (fr) | 2010-01-19 | 2011-07-28 | The Board Of Trustees Of The Leland Stanford Junior University | Conversion directe de cellules en cellules d'autres lignées |
| SG184440A1 (en) | 2010-04-08 | 2012-11-29 | Univ Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
| DK2561078T3 (en) | 2010-04-23 | 2019-01-14 | Cold Spring Harbor Laboratory | NEW STRUCTURALLY DESIGNED SHRNAs |
| GB201206773D0 (en) * | 2012-04-17 | 2012-05-30 | Cambridge Entpr Ltd | Stem cells from the mammalian neural plate |
| EP3008170A4 (fr) | 2013-06-11 | 2016-11-09 | Harvard College | Cellules dérivées de cellules souches et compositions et procédés pour générer ces cellules |
| US20220411759A1 (en) | 2019-05-21 | 2022-12-29 | President And Fellows Of Harvard College | Endocrine differentiation-inducing molecule |
| KR20240004504A (ko) | 2021-04-11 | 2024-01-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 심근세포 및 이를 생산하기 위한 조성물 및 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0658194A1 (fr) * | 1992-07-27 | 1995-06-21 | California Institute Of Technology | Cellules souches neurales pluripotentes de mammifere |
| DE19756864C5 (de) * | 1997-12-19 | 2014-07-10 | Oliver Brüstle | Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten |
| WO1999053021A1 (fr) * | 1998-04-09 | 1999-10-21 | Bresagen Limited | Facteur de differentiation/de proliferation et de conservation des cellules et procedes d'utilisation correspondants |
-
2001
- 2001-01-12 WO PCT/AU2001/000030 patent/WO2001051611A1/fr not_active Application Discontinuation
- 2001-01-12 WO PCT/AU2001/000029 patent/WO2001051610A1/fr active Application Filing
- 2001-01-12 EP EP01901033A patent/EP1254211A4/fr not_active Withdrawn
- 2001-01-12 CA CA002397292A patent/CA2397292A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1254211A4 (fr) | 2003-07-16 |
| WO2001051610A1 (fr) | 2001-07-19 |
| EP1254211A1 (fr) | 2002-11-06 |
| WO2001051611A1 (fr) | 2001-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2397292A1 (fr) | Production de cellules | |
| Rathjen et al. | Directed differentiation of pluripotent cells to neural lineages: homogeneous formation and differentiation of a neurectoderm population | |
| US7211434B2 (en) | Primitive neural stem cells and method for differentiation of stem cells to neural cells | |
| JP5982286B2 (ja) | 細胞の再プログラミングのための方法とその用途 | |
| KR100763477B1 (ko) | 사람 배아 줄기세포로부터 최종적으로 분화된 도파민작용성 뉴런의 유도 | |
| AU755028B2 (en) | Neural precursor cells, method for the production and use thereof in neural defect therapy | |
| US8809052B2 (en) | Methods of generating mature oligodendrocytes | |
| KR20190039434A (ko) | 만능 세포를 분화시키는 방법 | |
| JP4900587B2 (ja) | ヒト胚幹細胞由来の最終分化ドーパミン作動性神経細胞の誘導 | |
| EP1523549A2 (fr) | Oligodendrocytes derives de cellules souches embryonnaires humaines pour remyelinisation et traitement de lesion de la moelle epiniere | |
| JP2010536357A (ja) | 多能性幹細胞からのニューロン細胞の生成 | |
| Barald et al. | Immortalized cell lines from embryonic avian and murine otocysts: tools for molecular studies of the developing inner ear | |
| Osakada et al. | Neural induction and patterning in Mammalian pluripotent stem cells | |
| JP2023054306A (ja) | 無担体３ｄ球体浮遊培養における網膜ニューロン生成のための方法および組成物 | |
| Zholudeva et al. | Preparation of neural stem cells and progenitors: neuronal production and grafting applications | |
| US20070020608A1 (en) | Method for the generation of neural progenitor cells | |
| WO2013012269A2 (fr) | Procédé de production d'une cellule précurseur d'oligodendrocyte à partir d'une cellule souche pluripotente | |
| Billon et al. | Generation and characterization of oligodendrocytes from lineage-selectable embryonic stem cells in vitro | |
| US20030134413A1 (en) | Cell production | |
| AU2654401A (en) | Cell production | |
| KR20050083106A (ko) | 인간 배아줄기세포로부터 인간 신경전구세포주의 제조방법 | |
| Gillett | The effect of in vitro culture on the stability, expansion and neuronal differentiation of human pluripotent cell lines | |
| CA3195622A1 (fr) | Procedes de generation de cellules ciliees de l'oreille interne | |
| Bertacchi | In vitro neural differentiation of mouse embryonic stem cells: the positional identity of mouse ES-generated neurons is affected by BMP, Wnt and activin signaling | |
| Apicella | Embryonic stem cell-derived populations retain their tumorigenic potential |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |